Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling. / Risum, Malene; Barfod, Toke Seierøe.

I: Ugeskrift for Laeger, Bind 181, V08180568, 2019.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Risum, M & Barfod, TS 2019, 'Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling', Ugeskrift for Laeger, bind 181, V08180568. <https://ugeskriftet.dk/videnskab/forebyggelse-af-reaktivering-af-hepatitis-b-og-hepatitis-c-ved-immunsupprimerende>

APA

Risum, M., & Barfod, T. S. (2019). Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling. Ugeskrift for Laeger, 181, [V08180568]. https://ugeskriftet.dk/videnskab/forebyggelse-af-reaktivering-af-hepatitis-b-og-hepatitis-c-ved-immunsupprimerende

Vancouver

Risum M, Barfod TS. Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling. Ugeskrift for Laeger. 2019;181. V08180568.

Author

Risum, Malene ; Barfod, Toke Seierøe. / Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling. I: Ugeskrift for Laeger. 2019 ; Bind 181.

Bibtex

@article{cd585f0483d94610868c5ddb91500822,
title = "Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling",
abstract = "The use of immunosuppressive agents can be vital. However, immunosuppression may also cause reactivation of hepatitis B virus (HBV) infection which can be fatal. To reduce the risk of reactivation prophylactic antiviral treatment is recommended in patients with chronic HBV infection. In patients with former HBV infection prophylaxis is also recommended if anti-CD20 agents are used and in cases of transplantation. Immunosuppression in patients with hepatitis C virus (HCV) infection does not seem to lead to severe hepatic manifestations, and reactivation of HCV in this context generally has a mild clinical course.",
keywords = "Antiviral Agents, Hepacivirus, Hepatitis B/immunology, Hepatitis B virus, Hepatitis C/immunology, Humans, Immunosuppressive Agents/adverse effects, Virus Activation",
author = "Malene Risum and Barfod, {Toke Seier{\o}e}",
year = "2019",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",

}

RIS

TY - JOUR

T1 - Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling

AU - Risum, Malene

AU - Barfod, Toke Seierøe

PY - 2019

Y1 - 2019

N2 - The use of immunosuppressive agents can be vital. However, immunosuppression may also cause reactivation of hepatitis B virus (HBV) infection which can be fatal. To reduce the risk of reactivation prophylactic antiviral treatment is recommended in patients with chronic HBV infection. In patients with former HBV infection prophylaxis is also recommended if anti-CD20 agents are used and in cases of transplantation. Immunosuppression in patients with hepatitis C virus (HCV) infection does not seem to lead to severe hepatic manifestations, and reactivation of HCV in this context generally has a mild clinical course.

AB - The use of immunosuppressive agents can be vital. However, immunosuppression may also cause reactivation of hepatitis B virus (HBV) infection which can be fatal. To reduce the risk of reactivation prophylactic antiviral treatment is recommended in patients with chronic HBV infection. In patients with former HBV infection prophylaxis is also recommended if anti-CD20 agents are used and in cases of transplantation. Immunosuppression in patients with hepatitis C virus (HCV) infection does not seem to lead to severe hepatic manifestations, and reactivation of HCV in this context generally has a mild clinical course.

KW - Antiviral Agents

KW - Hepacivirus

KW - Hepatitis B/immunology

KW - Hepatitis B virus

KW - Hepatitis C/immunology

KW - Humans

KW - Immunosuppressive Agents/adverse effects

KW - Virus Activation

M3 - Tidsskriftartikel

C2 - 30729919

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V08180568

ER -

ID: 240953190